Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation
Authors:
- 26 January 2016
- journal article
- review article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 16 (3) , 209-219
Abstract
The Pharmacogenomics Journal is dedicated to the rapid publication of original research on basic pharmacogenomics research and its clinical applications.Keywords
This publication has 67 references indexed in Scilit:
- Meta-analysis of associations between TCF7L2 polymorphisms and risk of type 2 diabetes mellitus in the Chinese populationBMC Medical Genetics, 2013
- The KCNJ11 E23K gene polymorphism and type 2 diabetes mellitus in the Chinese Han population: a meta-analysis of 6,109 subjectsMolecular Biology Reports, 2012
- Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in Egyptian patients with type 2 diabetesTherapeutic Advances in Endocrinology and Metabolism, 2011
- TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetesBMC Medical Genetics, 2011
- Pharmacogenetics in type 2 diabetes: potential implications for clinical practiceGenome Medicine, 2011
- Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphismsExpert Review of Cardiovascular Therapy, 2010
- Type 2 Diabetes Susceptibility Gene TCF7L2 and Its Role in β-Cell FunctionDiabetes, 2009
- Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic PatientsDiabetes Care, 2008
- TCF7L2Polymorphisms and Progression to Diabetes in the Diabetes Prevention ProgramNew England Journal of Medicine, 2006
- Activating Mutations in the Gene Encoding the ATP-Sensitive Potassium-Channel Subunit Kir6.2 and Permanent Neonatal DiabetesNew England Journal of Medicine, 2004